The incremental impact of autologous hematopoietic cell transplantation (AHCT) on disease
burden with quadruplet induction in newly diagnosed multiple myeloma (NDDM) can be …

We evaluated toxicity, engraftment, chimerism, graft-versus-host disease (GVHD), and
response to a dose-reduced allograft after cytoreductive autografting in 17 patients with …

Autologous hematopoietic cell transplantation (AHCT) as initial therapy of patients with
multiple myeloma (MM) improves survival. However, data to support this approach for …

Within this retrospective single-center study, we analyzed the survival of 320 multiple
myeloma (MM) patients receiving melphalan high-dose chemotherapy (HDCT) and either …

Multiple myeloma ASCT must be integrated within a more global therapeutic approach
including new and more effective induction, consolidation, and maintenance approaches …

Collection of hematopoietic progenitor cells (HPC) after previous autologous hematopoietic
progenitor cell transplant (aHCT) was studied in 221 patients with multiple myeloma (MM) …

Abstract Background The EMN02/HO95 trial is the largest multicenter, randomized, phase 3
study conducted in the novel agent era and aimed to prospectively compare (randomization …

Over the last two decades, the utilization of various novel therapies in the upfront or salvage
settings has continued to improve survival outcomes for patients with Multiple Myeloma …

Autologous stem cell transplantation (ASCT) is an important treatment modality in multiple
myeloma (MM). However, relapse following ASCT is considered almost inevitable. This …

Purpose: To determine in a prospective study the efficacy, toxicity, and long-term outcome of
up-front allogeneic stem-cell transplantation (allo-SCT) in multiple myeloma (MM). Patients …